Philippines halts sale of Sanofi dengue vaccine amid health risk

A government nurse holds up a vial of Dengvaxia, the earth's first licensed dengue vaccine on April 4, 2016 in Manila, Philippines.

Dondi Tawatao | Getty Images

A government nurse holds up a vial of Dengvaxia, the earth’s first licensed dengue vaccine on April 4, 2016 in Manila, Philippines.

The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution along with marketing of its Dengvaxia dengue vaccine inside country after the company last week warned in which could worsen the disease in some cases.

The move comes days after the Southeast Asian nation suspended a government program to immunize hundreds of thousands of children with Dengvaxia following Sanofi’s findings released last week.

“In order to protect the general public, the Food along with Drug Administration immediately directed Sanofi to suspend the sale/distribution/marketing of Dengvaxia along with cause the withdrawal of Dengvaxia inside market pending compliance with the directives of the FDA,” the Philippine government agency said in a statement on its website released late on Monday.

The FDA also directed Sanofi to conduct an information dissemination campaign along with said all drug establishments should report any incidence in which showed Dengvaxia has caused death or serious illness to any person.

Sanofi officials said on Monday in which there had been no reported deaths related to the vaccine which was used to immunize nearly 734,000 children aged 9 along with over inside Philippines.

They have received at least one dose of the vaccine as part of a government program in which cost 3.5 billion pesos ($69.13 million).

Dengvaxia, the first approved dengue vaccine, had been forecast by Sanofi to eventually bring in nearly $1 billion in annual sales.

although even recent more modest analysts’ sales forecasts are right now looking unattainable given the safety issue along with clinical evidence revealing unequal protection against different strains of dengue.

the earth Health Organization said on Monday in which hopes to review safety data on Sanofi’s dengue vaccine in which month. The fears involve possible increased risk to people who had not previously been exposed to the dengue virus prior to vaccination with Dengvaxia.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

13 − 8 =